← 產業報告目錄
HIV Drugs Market Size, Share & Trends Analysis Report By Drug Type (Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Integrase Inhibitors, Entry and Fusion Inhibitors, Combination Class Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, And Segment Forecasts, 2025-2034
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-01-24頁數 170報告編號 INSIGHTACE-db18148f4d
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
A CAGR of 4.4% is forecasted for the global HIV Drugs Market over the assessment period of 2025 through 2034.
HIV Drugs covers reshaping how healthcare entities approach this space.
The market's upward path is driven by escalating healthcare spending, technological evolution, and the escalating focus on personalized and precision-based approaches in healthcare.
From a segmentation standpoint, the market is categorized across multiple dimensions including product type, application, end-user, and geography, each exhibiting distinct growth patterns and opportunities.
Regional dynamics show North America and Europe as established hubs, with the Asia-Pacific region set to deliver the strongest growth trajectory through the forecast period, driven by demographic shifts and policy support.
The competitive arena features a mix of established conglomerates and agile innovators, each vying for market position through strategic acquisitions, product launches, and capacity expansion.
The research provides an in-depth evaluation of market forces, competitive positioning, segmental dynamics, and regional trends, equipping stakeholders with actionable intelligence for the forecast period.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global HIV Drugs Market Snapshot
Chapter 4. Global HIV Drugs Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Clinical Trial/Pipeline Analysis
4.5. Industry Analysis – Porter's Five Forces Analysis
4.6. Clinical Trial Analysis 2019
4.7. COVID 19 Impact Analysis
Chapter 5. Market Segmentation 1: Drug Type Estimates & Trend Analysis
5.1. Drug Type & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Drug Type:
5.2.1. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
5.2.2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
5.2.3. Protease Inhibitors (PIs)
5.2.4. Integrase Inhibitors
5.2.5. Entry and Fusion Inhibitors
5.2.6. Combination Class Drugs
Chapter 6. Market Segmentation 2: Distribution Channel Estimates & Trend Analysis
6.1. Distribution Channel & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Distribution Channel:
6.2.1. Hospital Pharmacies
6.2.2. Retail Pharmacies
6.2.3. Online Pharmacies
Chapter 6. HIV Drugs Market Segmentation 3: Regional Estimates & Trend Analysis
6.1. North America
6.1.1. North America HIV Drugs Market revenue (US$ Million) estimates and forecasts by drug type, 2021 to 2034
6.1.1. North America HIV Drugs Market revenue (US$ Million) estimates and forecasts by distribution channel, 2021 to 2034
6.1.2. North America HIV Drugs Market revenue (US$ Million) estimates and forecasts by country, 20
6.1.2.1. U.S.
6.1.2.2. Canada
6.2. Europe
6.2.1. Europe HIV Drugs Market revenue (US$ Million) by drug type, 2021 to 2034
6.2.1. Europe HIV Drugs Market revenue (US$ Million) by distribution channel, 2021 to 2034
6.2.2. Europe HIV Drugs Market revenue (US$ Million) by country, 2021 to 2034
6.2.2.1. Germany
6.2.2.2. Poland
6.2.2.3. France
6.2.2.4. Italy
6.2.2.5. Spain
6.2.2.6. UK
6.2.2.7. Rest of Europe
6.3. Asia Pacific
6.3.1. Asia Pacific HIV Drugs Market revenue (US$ Million) by drug type, 2021 to 2034
6.3.1. Asia Pacific HIV Drugs Market revenue (US$ Million) by distribution channel, 2021 to 2034
6.3.2. Asia Pacific HIV Drugs Market revenue (US$ Million) by country, 2021 to 2034
6.3.2.1. China
6.3.2.2. India
6.3.2.3. Japan
6.3.2.4. Australia
6.3.2.5. Rest of Asia Pacific
6.4. Latin America
6.4.1. Latin America HIV Drugs Market revenue (US$ Million) by drug type, (US$ Million) 2021 to 2034
6.4.1. Latin America HIV Drugs Market revenue (US$ Million) by distribution channel, (US$ Million) 2021 to 2034
6.4.2. Latin America HIV Drugs Market revenue (US$ Million) by country, (US$ Million) 2021 to 2034
6.4.2.1. Brazil
6.4.2.2. Rest of Latin America
6.5. MEA
6.5.1. MEA revenue HIV Drugs Market revenue (US$ Million) by drug type, (US$ Million) 2021 to 2034
6.5.1. MEA revenue HIV Drugs Market revenue (US$ Million) by distribution channel, (US$ Million) 2021 to 2034
6.5.2. MEA revenue HIV Drugs Market revenue (US$ Million) by country, (US$ Million) 2021 to 2034
6.5.2.1. South Africa
6.5.2.2. Rest of MEA
Chapter 7. Competitive Landscape
7.1. Major Mergers and Acquisitions/Strategic Alliances
7.2. Company Profiles
7.2.1. Gilead Sciences
7.2.2. ViiV Healthcare
7.2.3. Janssen
7.2.4. Bristol-Myers Squibb
7.2.5. TaiMed Biologics
7.2.6. CytoDyn
7.2.7. Boehringer Ingelheim International GmbH
7.2.8. Merck & Co. Inc.
7.2.9. AbbVie
7.2.10. F. Hoffmann-La Roche Ltd.
7.2.11. Teva Pharmaceutical Industries Ltd.
7.2.12. Cipla Limited
7.2.13. Daiichi Sankyo
7.2.14. Emcure
7.2.15. Hetero Drugs
7.2.16. Mylan
7.2.17. Shantou Huatai Pharmaceutical Co., Ltd.
7.2.18. Shengzhen Chongway Biotechnology Co., Ltd.
7.2.19. Other Prominent Player
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們